It has also aggressively invested in gene editing, including its 2025 acquisition of cardiovascular disease gene-editing ...

The gene-editing niche of the biotech industry is gaining momentum, as various companies focused on these techniques -- which allow scientists to alter patients' DNA to treat some diseases -- have ...

View Taysha Gene Therapies, Inc. TSHA stock quote prices, financial information, real-time forecasts, and company news from CNN.

View Ocugen Inc OCGN stock quote prices, financial information, real-time forecasts, and company news from CNN.

Rocket Pharmaceuticals Inc (NASDAQ:RCKT) is one of the best gene therapy stocks to buy in 2026. The Street expects Rocket Pharmaceuticals’ stock to explode 180% over the next 12 months. On April 28, ...

Get the live share price of Sarepta Therapeutics Inc (SRPT), including intraday charts, historical performance, key financials, and market updates. Track the latest US stock market activity.

One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk profiles stack up for 2026.

Is TSHA a good stock to buy? We came across a bullish thesis on Taysha Gene Therapies, Inc. on BioEquity Watch’s Substack. In ...

Taysha Gene Therapies is now a one-drug company, fully reliant on TSHA-102 for Rett syndrome after discontinuing its previous ...

AI-driven health intelligence provider GeneDx attracted a notable insider buy, as recent filings highlight activity amid a volatile year.